Cyana Therapeutics is a precision immuno-oncology company developing drugs to treat solid tumors. Our lead compound (CY-3132) is a small molecule inhibitor of an enzyme called ENPP1, which is upregulated on the surface of many tumor cells.
Cyana Therapeutics is a precision immuno-oncology company developing drugs to treat solid tumors. Our lead compound (CY-3132) is a small molecule inhibitor of an enzyme called ENPP1, which is upregulated on the surface of many tumor cells. ENPP1 activity allows tumor cells to evade the immune system, and tumors expressing high levels of ENPP1 are often resistant to current cancer treatments. By blocking ENPP1 activity, CY-3132 restores cancer cell immune signaling, activating the body's ability to recognize and eliminate cancer cells.
The ENPP1 enzyme is part of the cGAS-STING pathway, which controls immune signaling in the body. High ENPP1 expression level on tumor cells allows the tumor to evade the body's immune system. ENPP1 expression on tumor cells has been correlated with low survival rates in cancer patients.
Blocking ENPP1 in tumor cell lines and animal models increases survival and improves response to cancer treatments by turning “cold” tumors into “hot” tumors that the body can recognize and target.
High expression of ENPP1 is seen in multiple solid tumor types, including:
CY-3132 is a small molecule inhibitor of ENPP1 for the treatment of solid tumors. By blocking ENPP1 activity, CY-3132 transforms tumor cells from immune evading to immune activating. CY-3132 has been tested in many solid tumor cell lines and animal models that have traditionally been resistant to treatment, including breast cancer, colorectal cancer, pancreatic cancer and lung cancer.
Whether you’re interested in partnerships, investment opportunities, or learning more about our science, we’re here to connect.
